The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance

Summary: The calibrated population resistance (CPR) tool is a web-accessible program for performing standardized genotypic estimation of transmitted HIV-1 drug resistance. The program is linked to the Stanford HIV drug resistance database and can additionally perform viral genotyping and algorithmic estimation of resistance to specific antiretroviral drugs. Availability: http://cpr.stanford.edu/cpr/index.html Contact: robjgiff@gmail.com

[1]  Soo-Yon Rhee,et al.  Consensus Drug Resistance Mutations for Epidemiological Surveillance: Basic Principles and Potential Controversies , 2008, Antiviral therapy.

[2]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[3]  D. Bennett,et al.  The World Health Organization's global strategy for prevention and assessment of HIV drug resistance , 2008, Antiviral therapy.

[4]  Paul Sandstrom,et al.  HIV-1 drug resistance surveillance using dried whole blood spots , 2007, Antiviral therapy.

[5]  Spread programme,et al.  Transmission of drug-resistant HIV-1 in Europe remains limited to single classes , 2008, AIDS.

[6]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[7]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[8]  John P. Walsh,et al.  Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom , 2007, AIDS.

[9]  D. Bennett,et al.  Darunavir: pharmacokinetics and drug interactions. , 2008 .

[10]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[11]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[12]  Deenan Pillay,et al.  Current Patterns in the Epidemiology of Primary HIV Drug Resistance in North America and Europe , 2004, Antiviral therapy.

[13]  Annemarie M. J. Wensing,et al.  The Epidemiology of Transmission of Drug Resistant HIV-1 , 2007 .

[14]  Soo-Yon Rhee,et al.  Sequence editing by Apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance , 2008, AIDS.

[15]  J. Zhang,et al.  Methods for comparing a DNA sequence with a protein sequence , 1996, Comput. Appl. Biosci..

[16]  Jörg Schüpbach,et al.  Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey , 2007, AIDS.

[17]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[18]  A. Harrison,et al.  A statistical model for HIV-1 sequence classification using the subtype analyser (STAR) , 2005, Bioinform..

[19]  M. Malim,et al.  APOBEC-mediated viral restriction: not simply editing? , 2007, Trends in biochemical sciences.

[20]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.